Merck (NYSE: MRK) reported Q3 EPS of $1.57, $0.07 better than the analyst estimate of $1.50. Revenue for the quarter came in at $16.66 billion versus the consensus estimate of $16.45 billion.

GUIDANCE:

Merck sees FY2024 EPS of $7.72-$7.77, versus the consensus of $7.74. Merck sees FY2024 revenue of $63.6-64.1 billion, versus the consensus of $64.15 billion.

For earnings history and earnings-related data on Merck (MRK) click here.